Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an antisense oligonucleotide lowering lipoprotein(a)—both failed to reduce major adverse cardiovascular events despite effectively lowering their respective biomarkers. In the ziltivekimab trial, 6,376 adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation (high-sensitivity […]